-transparent.png){kind=logo}
A multicentre, randomized clinical trial of antilymphocyte globulin (ALG) was conducted among patients who had undergone cadaver kidney transplantation; follow-up was continued for a minimum of 1 year. Of the 179 patients 92 were given conventional treatment only, while 87 were given in addition ALG (from a standardized, highly immunosuppressive, common pool of equine ALG), 20 mg/kg-d intravenously for 10 days after transplantation. The ALG-treated group had better accumulated graft survival, fewer nephrectomies, better graft function, less than half the number of acute rejection episodes and less prednisone use. There was a beneficial drug (ALG)-related effect in both the graft and the host during the first 3 months after transplantation.
H E Taylor, and
C F Ackman, and
I Horowitz
January 1971,
Surgical forum,
H E Taylor, and
C F Ackman, and
I Horowitz
June 1986,
Transplantation proceedings,
H E Taylor, and
C F Ackman, and
I Horowitz
April 1986,
Transplantation proceedings,
H E Taylor, and
C F Ackman, and
I Horowitz
February 1971,
Lancet (London, England),
H E Taylor, and
C F Ackman, and
I Horowitz
March 1971,
Transplantation proceedings,
H E Taylor, and
C F Ackman, and
I Horowitz
January 1968,
Surgical forum,
H E Taylor, and
C F Ackman, and
I Horowitz
January 1977,
Scandinavian journal of urology and nephrology. Supplementum,
H E Taylor, and
C F Ackman, and
I Horowitz
January 1976,
Postgraduate medical journal,
H E Taylor, and
C F Ackman, and
I Horowitz
March 1971,
Transplantation proceedings,
H E Taylor, and
C F Ackman, and
I Horowitz
May 1983,
The Urologic clinics of North America,
